These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16274557)

  • 21. Early Implanon discontinuation rate and its associated factors in health institutions of Mekelle City, Tigray, Ethiopia 2016/17.
    G/Medhin T; Gebrekidan KG; Nerea MK; Gerezgiher H; Haftu M
    BMC Res Notes; 2019 Jan; 12(1):8. PubMed ID: 30616681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to remove impalpable Implanon implants.
    Walling M
    J Fam Plann Reprod Health Care; 2005 Oct; 31(4):320-1. PubMed ID: 16274562
    [No Abstract]   [Full Text] [Related]  

  • 23. Indications for removal of etonogestrel implant within two years of use in Jos, Nigeria.
    Mutihir JT; Nyango DD
    East Afr Med J; 2010 Nov; 87(11):461-4. PubMed ID: 23457809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Contraceptive implants--aberrations from insertion and removal procedures].
    Jørgensen NP
    Tidsskr Nor Laegeforen; 2010 Apr; 130(7):733-4. PubMed ID: 20379334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acceptability of the etonogestrel-containing contraceptive implant (Implanon)].
    Sergent F; Clamageran C; Bastard AM; Verspyck E; Marpeau L
    J Gynecol Obstet Biol Reprod (Paris); 2004 Sep; 33(5):407-15. PubMed ID: 15480280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A randomized study comparing the efficacy and bleeding pattern of Implanon and Norplant hormonal contraceptive implant].
    Yao XY; Du MK
    Zhonghua Fu Chan Ke Za Zhi; 2003 Jul; 38(7):419-22. PubMed ID: 12921554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One year study of Implanon on the adverse events and discontinuation.
    Chaovisitsaree S; Piyamongkol W; Pongsatha S; Morakote N; Noium S; Soonthornlimsiri N
    J Med Assoc Thai; 2005 Mar; 88(3):314-7. PubMed ID: 15962637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A qualitative study on reasons for early removal of Implanon among users in Arba Minch town, Gamo Goffa zone, South Ethiopia: a phenomenological approach.
    Utaile MM; Debere MK; Nida ET; Boneya DJ; Ergano AT
    BMC Womens Health; 2020 Jan; 20(1):2. PubMed ID: 31896349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contraceptive efficacy and side effects of Implanon.
    Gezginc K; Balci O; Karatayli R; Colakoglu MC
    Eur J Contracept Reprod Health Care; 2007 Dec; 12(4):362-5. PubMed ID: 17853166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic analysis of long-term reversible contraceptives. Focus on Implanon.
    Phillips CJ
    Pharmacoeconomics; 2000 Feb; 17(2):209-21. PubMed ID: 10947343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Implanon insertion and removal.
    Levine JP; Sinofsky FE; Christ MF;
    Contraception; 2008 Nov; 78(5):409-17. PubMed ID: 18929739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contraceptive implants.
    Ladipo O; Coutinho EM
    Curr Opin Obstet Gynecol; 1994 Dec; 6(6):564-9. PubMed ID: 7893965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year continuation of the etonogestrel contraceptive implant in women with postabortion or interval placement.
    Mark A; Sonalkar S; Borgatta L
    Contraception; 2013 Nov; 88(5):619-23. PubMed ID: 23790436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey.
    Yildizbas B; Sahin HG; Kolusari A; Zeteroglu S; Kamaci M
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):248-52. PubMed ID: 17763263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon).
    Yisa SB; Okenwa AA; Husemeyer RP
    J Fam Plann Reprod Health Care; 2005 Jan; 31(1):67-70. PubMed ID: 15720856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of patients' challenges and barriers related to usage of Implanon®: scoping review protocol.
    Prosad S; Mashamba-Thompson TP; Ojewole E
    Syst Rev; 2018 Oct; 7(1):157. PubMed ID: 30309380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain.
    Arribas-Mir L; Rueda-Lozano D; Agrela-Cardona M; Cedeño-Benavides T; Olvera-Porcel C; Bueno-Cavanillas A
    Contraception; 2009 Nov; 80(5):457-62. PubMed ID: 19835720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In situ breakage of Implanon®--two cases of a rare occurrence.
    Torres R; Mendes N; Machado AI; Marques C
    Contraception; 2013 Jul; 88(1):189-91. PubMed ID: 23218858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implanon use in Thai women above the age of 35 years.
    Booranabunyat S; Taneepanichskul S
    Contraception; 2004 Jun; 69(6):489-91. PubMed ID: 15157794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience.
    Graesslin O; Korver T
    Eur J Contracept Reprod Health Care; 2008 Jun; 13 Suppl 1():4-12. PubMed ID: 18330813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.